R&D Lessons from Pfizer's New Breast Cancer Drug, PD-332,991

cp418

http://www.forbes.com/sites/johnlamattina/2012/12/20/rd-lessons-from-pfizers-new-breast-cancer-drug-pd-332991/

R&D Lessons from Pfizer's New Breast Cancer Drug, PD-332,991

cp418

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76080

A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.